In a recent meeting of the New Hampshire House Special Committee on COVID Response Efficacy, significant discussions emerged regarding the troubling rise in abnormal blood clotting associated with COVID-19 and its vaccines. Medical experts shared insights into how these coagulation issues are impacting public health, raising concerns for many residents.

One of the key topics was the unusual clotting patterns observed in individuals who have died, as reported by funeral home directors and autopsy results. Experts noted that the nature of these clots differs from typical thrombus formations, making them harder to break down. This abnormality is linked to the spike protein of the virus, which alters the structure of fibrin, a protein essential for blood clotting. As a result, individuals with genetic predispositions to clotting issues may experience compounded health risks, leading to conditions such as deep vein thrombosis, pulmonary embolisms, and strokes.

The committee also explored the prevalence of coagulopathy—abnormal clotting—among those vaccinated and those who have contracted COVID-19. Research indicates that exposure to the spike protein, whether through infection or vaccination, can lead to the production of abnormal fibrin. However, the extent of symptoms and complications varies among individuals, depending on their ability to manage this abnormality.

In response to these findings, medical professionals are increasingly turning to anticoagulant and antiplatelet therapies as potential treatments for patients experiencing these complications. Early data from hospitals indicated that patients on blood thinners had better outcomes, prompting further investigation into these treatments for outpatient care. One physician reported a success rate of approximately 70% in returning patients to normal status after administering dual therapy.

The discussions highlighted a shift in understanding COVID-19 as not just a respiratory illness but a vascular disease that affects the body's coagulation system. This evolving perspective emphasizes the need for continued research into the long-term effects of COVID-19 and its vaccines on vascular health.

As the committee continues to address these pressing health concerns, the implications for public health policy and community well-being remain significant. The findings underscore the importance of monitoring and treating coagulation issues as part of the ongoing response to the pandemic, ensuring that residents receive the care they need to navigate these complex health challenges.